Home
NewsNewsMochida Grants LG Chem Endometriosis Drug Licensing to develop and sell Dinagest that has an active ingredient, Dienogest, that halts endometrial cells from growing, offering a non-hormonal therapeutic option for women suffering from endometriosis.
Mochida Pharmaceutical, which is based in Japan, and LG Chem, which is based in South Korea, have made a deal to work together on Dinagest. Mochida sells Dinagest in Japan, where it is used to treat endometriosis as well as other conditions.
As part of the endometriosis drug licensing deal, Mochida has given LG Chem exclusive rights to develop and sell the product in South Korea and Thailand. LG Chem will get the necessary marketing approvals in each country and then make the product available to patients.
Dienogest, the active ingredient in Dinagest, is a progestin that stops the ovaries from working and halts endometrial cells from growing by selectively binding to the progesterone receptor.
Mochida introduced the product in Japan in 2008 and has been looking for ways to expand it into other countries. Mochida has also been working to grow its business operations around the world by 2031. As a result of these efforts, Mochida is moving forward with the product's first global expansion as part of this agreement.
For more than 30 years, LG Chem has been an expert in the research and production of hormone-based therapies for infertility treatment in the field of reproductive medicine. LG Chem continues to be a trusted partner in the field of reproductive medicine because it has high-quality products, does ongoing research and development, and is very dedicated to patients and doctors.
With Endometriosis Drug Licensing, Mochida has given LG Chem exclusive rights to develop and sell Dinagest. Apparently, both companies have worked together before on the biosimilars of etanercept and adalimumab. These products were subsequently released in Japan. Mochida and LG Chem want to get the product to patients in South Korea and Thailand and help them live better lives by way of this new agreement.
INVO Fertility, Inc has confirmed that its Wisconsin Fertility Institute-WFI clinic joined the Progyny network, making advanced reproductive care more widely available and accessible for more patients seeking fertility treatment.
Births resulting from essential Infertility Treatments, including advanced procedures like artificial insemination and IVF, have seen a very positive and promising climb, accounting for almost 15.1% of the total births recorded in 2024.
The Fertility Society of Ghana has urged the government to officially recognize infertility as a disease and include basic fertility services in the National Health Insurance Scheme during its eighth Annual General meeting, held in Tema.
Fairfax IVI expand donor sperm access through a strategic partnership that enhances availability, integrates donor services into fertility care, and supports diverse patient needs. With personalised guidance, genetic insights, and streamlined logistics, the collaboration aims to reduce barriers and deliver a more accessible, inclusive path to parenthood.
Researchers have developed breakthrough microfluidic technology that can accurately predict how an embryo is going to implant, directly addressing long-standing IVF challenges and offering new hope for improved success rates.
The Florida Supreme Court has clarified that its statute on reproductive technology does not apply to At-Home Artificial Insemination.
Costco, Sesame, and IVI RMA North America have announced strategic partnership to alter fertility care in the U.S. by removing biggest obstacles to care including high costs and limited access.
